Letter

Pandemic flu

Look at all the evidence before stockpiling amantadine

BMJ 2007; 334 doi: 10.1136/bmj.39136.489942.FA (Published 1 March 2007)
Cite this as: BMJ 2007;334:439.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Tom Jefferson, Cochrane Acute Respiratory Infections Group
  1. Anguillara Sabazia, Rome 00061, Italy
  1. jefferson.tom{at}gmail.com

    Tsiodras et al propose testing amantadine to see if any benefits could accrue in combination with neuraminidase inhibitors in pandemic flu.1 The principal attraction seems to be low cost. Although they quote resistance and harms as well as lack of “any demonstrable reduction in transmissibility or pathogenicity,” this does not seem to deter them from their proposal.

    Had they consulted the Cochrane Library, they …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular